The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study

Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction

(2021) Khaled Elkholey et al.   AMERICAN JOURNAL OF CARDIOLOGY

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

(2021) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

(2021) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obesity, kidney dysfunction and hypertension: mechanistic links

(2019) John E. Hall et al.   Nature Reviews Nephrology

Mineralocorticoid Receptors in Metabolic Syndrome: From Physiology to Disease

(2019) Alessandra Feraco et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

The relationship between increased ratio of visceral-to-subcutaneous fat area and renal outcome in Chinese adult with type 2 diabetes and diabetic kidney disease

(2018) Yiting Wang et al.   Canadian Journal of Diabetes

Modeling the impact of obesity on the lifetime risk of chronic kidney disease in the United States using updated estimates of GFR progression from the CRIC study

(2018) Benjamin O. Yarnoff et al.   PLoS One

Gain in adiposity over 3 years is associated with progressive renal decline in multi-ethnic South-East Asians with type 2 diabetes

(2018) Mei Chung Moh et al.   Journal of Diabetes

Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial

(2017) Arnaud Olivier et al.   EUROPEAN JOURNAL OF HEART FAILURE

The dual roles of obesity in chronic kidney disease

(2016) Connie M. Rhee et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study

(2016) Luke J. Laffin et al.   Journal of Clinical Hypertension

Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 SynthaseNovelty and Significance

(2015) Riccardo Urbanet et al.   HYPERTENSION

Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism

(2015) Shigehiro Karashima et al.   HYPERTENSION RESEARCH

High Body Mass Index Reduces Glomerular Filtration Rate Decline in Type II Diabetes Mellitus Patients With Stage 3 or 4 Chronic Kidney Disease

(2014) Wen-Hung Huang et al.   MEDICINE

Mineralocorticoid receptors modulate vascular endothelial function in human obesity

(2013) Moon-Hyon Hwang et al.   CLINICAL SCIENCE

Obesity in CKD--What Should Nephrologists Know?

(2013) P. Stenvinkel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Contribution of glucocorticoid–mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction

(2012) Ayumu Hirata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways

(2012) Ana M. Briones et al.   HYPERTENSION

Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE

(2010) Sébastien Czernichow et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Variability in Waist Circumference Measurements According to Anatomic Measurement Site

(2009) Caitlin Mason et al.   Obesity

Body Mass Index Predicts Plasma Aldosterone Concentrations in Overweight-Obese Primary Hypertensive Patients

(2008) Gian Paolo Rossi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM